You are here

SARC019

Completed
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
Type of Sarcoma: 
Metastatic GIST
Drug: 
Imatinib
Accrual Status: 
Terminated
Overall Study Principal Investigator: 

Suzanne George, MD
Dana-Farber Cancer Institute

For more information about this trial and open sites: